BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15073269)

  • 1. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
    Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
    J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
    de Jong M; Rolleman EJ; Bernard BF; Visser TJ; Bakker WH; Breeman WA; Krenning EP
    J Nucl Med; 1996 Aug; 37(8):1388-92. PubMed ID: 8708781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
    de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
    J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
    Rolleman EJ; Valkema R; de Jong M; Kooij PP; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):9-15. PubMed ID: 12483404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
    van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
    J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney.
    Rolleman EJ; Kooij PP; de Herder WW; Valkema R; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1854-60. PubMed ID: 17546456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.
    De Jong M; Valkema R; Van Gameren A; Van Boven H; Bex A; Van De Weyer EP; Burggraaf JD; Körner M; Reubi JC; Krenning EP
    J Nucl Med; 2004 Jul; 45(7):1168-71. PubMed ID: 15235063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
    Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide.
    Verwijnen SM; Krenning EP; Valkema R; Huijmans JG; de Jong M
    J Nucl Med; 2005 Dec; 46(12):2057-60. PubMed ID: 16330570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
    Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
    Melis M; Krenning EP; Bernard BF; Barone R; Visser TJ; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1136-43. PubMed ID: 15912401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
    Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
    Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
    Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
    J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy.
    de Jong M; Breeman WA; Bernard BF; Rolleman EJ; Hofland LJ; Visser TJ; Setyono-Han B; Bakker WH; van der Pluijm ME; Krenning EP
    Eur J Nucl Med; 1995 Jul; 22(7):608-16. PubMed ID: 7498221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redesign of negatively charged
    Oshima N; Akizawa H; Kawashima H; Zhao S; Zhao Y; Nishijima KI; Kitamura Y; Arano Y; Kuge Y; Ohkura K
    Nucl Med Biol; 2017 May; 48():16-25. PubMed ID: 28160666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
    Lin YC; Hung GU; Luo TY; Chen CH; Hsia CC; Hen SL; Ho YJ; Lin WY
    J Vet Med Sci; 2006 Apr; 68(4):367-71. PubMed ID: 16679728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.